Off the cnnfn wire's Aricept a top contender
Sales of Alzheimer's Disease Therapies Will Nearly Triple by
2007, Reports Decision Resources, Inc.
PRNewswire
WALTHAM, Mass., July 13 /PRNewswire/ --
Alzheimer's Disease (AD) afflicts nearly 7 million
people in the world's seven major pharmaceutical
markets (the United States, France, Germany,
Italy, Spain, the United Kingdom, and Japan). Over the past decade, both
the general public and the research community have focused heavily on AD,
yet no known therapy has demonstrated any clear-cut capacity to modify
the disease. Second-generation cholinesterase inhibitors, including
Pfizer/Eisai's Aricept, do have the ability to improve behavioral symptoms,
but offer modest benefits for memory and cognitive function.
In a new report titled Alzheimer's Disease, Decision Resources, Inc., takes
an in-depth look at this condition, providing detailed information on
epidemiology, etiology, pathophysiology, medical practice, current and
emerging therapies, and unmet medical needs. The report also provides a
detailed market assessment, which includes a sales forecast for the seven
major markets to 2007. In 1997, sales of drugs prescribed to treat AD in
the major markets were $650 million. We expect this figure to reach nearly
$1.9 billion by 2007, with the bulk of sales coming from cholinesterase
inhibitors. This report is part of Cognos, one of five therapeutically focused
services that evaluate the commercial potential of ethical drugs in research
and development. For more detailed report information, contact Frank
Sama, Marketing Manager, 781.487.3753, e-mail: sama@dresources.com.
Decision Resources, Inc., Bay Colony Corporate Center, 1100 Winter
Street, Waltham, MA 02451. Fax: 781.487.5750. In Europe, contact Ms.
Vera Bisegna, +32.2.351.1079 (telephone), +32.2.351.2347 (fax), or
vbisegna@compuserve.com (e-mail). In Japan, contact Ms. Makiko
Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or
makiko@bl.mmtr.or.jp (e-mail).
Decision Resources is a world leader in research publications, advisory
services, and consulting designed to help clients shape strategy, allocate
resources, and master their chosen markets. Founded as a subsidiary of
[ Arthur D. Little, Inc. ] , and employee-owned since 1990, Decision
Resources has provided strategic information services for over 25 years,
assessing global industry trends in the international health care and
pharmaceutical industries. Drawing on a closely linked international network
of experts, Decision Resources offers its clients the most comprehensive
analyses of therapy markets available today. SOURCE Decision Resources,
Inc.
(Copyright 1998)
_____via IntellX_____
Publication Date: July 13, 1998
Powered by NewsReal's IndustryWatch |
